Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases

被引:72
作者
Kobrynski, Lisa [1 ]
机构
[1] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA
关键词
primary immunodeficiency diseases; subcutaneous immunoglobulin; immuno-globulin G;
D O I
10.2147/BTT.S25188
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Since the 1950s, replacement of immunoglobulin G using human immunoglobulin has been the standard treatment for primary immunodeficiency diseases with defects in antibody production. These patients suffer from recurrent and severe infections, which cause lung damage and shorten their life span. Immunoglobulins given intravenously (IVIG) every 3-4 weeks are effective in preventing serious bacterial infections and improving the quality of life for treated patients. Administration of immunoglobulin subcutaneously (SCIG) is equally effective in preventing infections and has a lower incidence of serious adverse effects compared to IVIG. The tolerability and acceptability of SCIG has been demonstrated in numerous studies showing improvements in quality of life and a preference for subcutaneous immunoglobulin therapy in patients with antibody deficiencies.
引用
收藏
页码:277 / 287
页数:11
相关论文
共 92 条
  • [1] Primary immunodefciency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Priary Immunodeficiency
    Al-Herz, Waleed
    Bousfiha, Aziz
    Casanova, Jean-Laurent
    Chapel, Helen
    Conley, Mary Ellen
    Cunningham-Rundles, Charlotte
    Etzioni, Amos
    Fischer, Alain
    Luis Franco, Jose
    Geha, Raif S.
    Hammarstrom, Lennart
    Nonoyama, Shigeaki
    Notarangelo, Luigi Daniele
    Ochs, Hans Dieter
    Puck, Jennifer M.
    Roifman, Chaim M.
    Seger, Reinhard
    Tang, Mimi L. K.
    [J]. FRONTIERS IN IMMUNOLOGY, 2011, 2
  • [2] [Anonymous], 2011, HIZ IMM GLOB SUBC HU
  • [3] [Anonymous], 2010, GAM C IMM GLOB INJ H
  • [4] [Anonymous], 2012, GAMM LIQ IMM GLOB IN
  • [5] [Anonymous], 2011, GAMM TRAD IMM GLOB I
  • [6] [Anonymous], 2010, VIV REG IMM GLOB SUB
  • [7] Safety of IGIV therapy and infusion-related adverse events
    Ballow, Mark
    [J]. IMMUNOLOGIC RESEARCH, 2007, 38 (1-3) : 122 - 132
  • [8] Bayrakci B, 2005, TURKISH J PEDIATR, V47, P239
  • [9] Safety, efficacy, and pharmacokinetics of Flebogamma® 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases
    Berger, M
    Pinciaro, PJ
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2004, 24 (04) : 389 - 396
  • [10] IMMUNOGLOBULIN REPLACEMENT THERAPY BY SLOW SUBCUTANEOUS INFUSION
    BERGER, M
    CUPPS, TR
    FAUCI, AS
    [J]. ANNALS OF INTERNAL MEDICINE, 1980, 93 (01) : 55 - 56